Silence Therapeutics Plc (SLN)

Add to research

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Company performance
Add to research
View more

Current Price

as of Jun 18, 2025

$5.66

P/E Ratio

N/A

Market Cap

$267.32M

Description
Add to research
View more

Silence Therapeutics Plc engages in the discovery, delivery, and development of ribonucleic acid (RNA) therapeutics. It also develops medicines by harnessing the body's natural mechanism of RNA interference within its cells. The company was founded on November 18, 1994 and is headquartered in London, the United Kingdom.

Metrics
Add to research
View more

Overview

  • HQLondon, GL
  • SectorCommercial Services
  • IndustryMiscellaneous Commercial Services
  • TickerSLN
  • Price$5.66+5.40%

Trading Information

  • Market cap$267.32M
  • Float79.63%
  • Average Daily Volume (1m)122,050
  • Average Daily Volume (3m)215,694
  • EPS-$0.98

Company

  • Revenue$43.28M
  • Rev growth (1yr)-99.09%
  • Net income-$28.64M
  • Gross margin-9.51%
  • EBITDA margin-18,022.54%
  • EBITDA-$25.69M
  • EV-$3.30M
  • EV/Revenue-0.08
  • P/EN/A
  • P/S6.18
  • P/B2.37
  • Debt/Equity0.05
Documents
Add to research
View more